Low-dose statins restore innate immune response in breast cancer cells via suppression of mutant p53
The findings suggest low-dose statins can enhance innate immunity in breast cancer by degrading mutant p53, offering new treatment possibilities. Caution is advised, and further research is needed to address limitations and provide solid evidence for clinical use.
Authors
- Beijia Liu (ORCID: https://orcid.org/0000-0001-7765-9709)
- Tien‐Min Gabriel Chu (ORCID: https://orcid.org/0000-0002-7190-837X)
- Zifeng Huang (ORCID: https://orcid.org/0000-0002-7299-8303)
- Zi Wang (ORCID: https://orcid.org/0000-0002-6859-8569)
- Xuening Zhang (ORCID: https://orcid.org/0000-0002-2261-5212)
- Yanchao Yang (ORCID: https://orcid.org/0000-0002-2447-7917)
- Wenzhe Ma
- Meina Shi
- Dayuan Zheng
- Wanjun Lin
- Dongfan Yang
Institutions
- Macau University of Science and Technology (MO)
Publication Details
- Journal
- Frontiers in Pharmacology
- Published
- 2025-05-02
- DOI
- https://doi.org/10.3389/fphar.2025.1492305
- Citations
- 1
- Primary Topic
- interferon and immune responses
- Type
- article
- Field-Weighted Citation Impact
- 0.80